Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors.

OBJECTIVES: In order to assess the potential biomolecules for breast cancer, we analyzed in parallel the levels of cell-free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cell-free nucleosomes in serum samples from patients with benign and malignant breast tumors. The levels of cell-free DNA obtained by quantitative PCR were compared with those obtained by enzyme-linked immunosorbent assay (ELISA). METHODS: Twenty-three patients with benign breast tumors, 27 patients with breast cancer, and 32 age-matched healthy women were recruited. The amounts of serum nucleosomes were analyzed by ELISA and the levels of cell-free GAPDH were measured by real-time quantitative PCR. The correlation between nucleosome and cell-free GAPDH levels was examined using the Spearman rank test. RESULTS: The levels of cell-free GAPDH were significantly higher in the serum samples of patients with benign and malignant breast tumors than in those of the control group (median 37,966 GE/mL, range 3,802-130,104 versus 11,770 GE/mL, range 2,198-73,522, p=0.035 and median 40,698 GE/mL, range 3,644-192,482 versus 11,770 GE/mL range 2,198-73,522, p=0.001). The concentration of cell-free GAPDH correlated significantly with the quantities of nucleosomes in serum samples (r=0.451, p=0.000). There was, however, no significant difference between healthy individuals and women with benign breast tumors or breast cancer in terms of nucleosomes determined by ELISA. CONCLUSION: Our data suggest that the cell-free serum GAPDH DNA assayed by quantitative PCR is a better biomarker than nucleosomes assayed by ELISA in patients with breast tumors.

Advances in broad bandwidth light sources for ultrahigh resolution optical coherence tomography.

Novel ultra-broad bandwidth light sources enabling unprecedented sub-2 microm axial resolution over the 400 nm-1700 nm wavelength range have been developed and evaluated with respect to their feasibility for clinical ultrahigh resolution optical coherence tomography (UHR OCT) applications. The state-of-the-art light sources described here include a compact Kerr lens mode locked Ti:sapphire laser (lambdaC = 785 nm, delta lambda = 260 nm, P(out) = 50 mW) and different nonlinear fibre-based light sources with spectral bandwidths (at full width at half maximum) up to 350 nm at lambdaC = 1130 nm and 470 nm at lambdaC = 1375 nm. In vitro UHR OCT imaging is demonstrated at multiple wavelengths in human cancer cells, animal ganglion cells as well as in neuropathologic and ophthalmic biopsies in order to compare and optimize UHR OCT image contrast, resolution and penetration depth.

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

An SAR study of a screening lead has led to the identification of 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as inhibitors of Staphylococcus aureus enoyl acyl carrier protein reductase (FabI).

[Kennedy disease: report of 2 cases]. / Doença de Kennedy: relato de dois casos.

We report two cases of Kennedy's disease (muscle weakness, amyotrophy, intentional tremor, endocrine abnormalities, and denervation signs at electromyography). This entity must be differentiated from other motor neuron disorders by the genetic pattern (X-liked recessive), gynecomastia, testicular atrophy, oligospermia and good prognosis. A discussion about the clinical pattern and evolution is made.

Doença de Kennedy: relato de dois casos / Kennedy disease: report of 2 cases

Relatamos, pela primeira vez em nosso meio, dois pacientes com atrofia muscular bulbo espinhal de início tardio (doença de Kennedy), caracterizada por fraqueza, atrofia muscular, tremores e manifestaçöes endocrinológicas, com sinais eletromiográficos de desnervaçäo. Esta entidade diferencia-se das demais doenças do neurônio motor pela sua peculiar herança ligada ao sexo, anormalidades endocrinas (ginecomastia, atrofia testicular e oligoespermia), tendo prognóstico relativamente favorável. Discutimos a caracterizaçäo clínica dos doentes apresentados, o aspecto fisiopatológico e a evoluçäo

Effects of sustained low-level muscarinic agonism in rats.

Sustained, low level muscarinic activity was induced in rats by feeding the muscarinic agonist and experimental drug candidate CI-969 at 50, 100 and 200 mg/kg body weight/day for 4 wk. Except for urine staining, clinical signs typical of acute high-dose exposure to muscarinic agonists were not observed. A dose-related suppression of body weight gain approached 60% at the high dose, but no significant effects on haematology or clinical chemical parameters were observed after 4 wk of exposure. Corneal opacities with histopathological features including neovascularization, acanthosis and stromal proliferation were observed in a dose-related fashion in both sexes at 100 and 200 mg/kg/day. Hypertrophy of the Harderian and lacrimal glands also occurred, probably as an adaptive response to sustained muscarinic activity. Lacrimal gland concentrations of the muscarinic agonist were in the range of pmol/mg tissue and therefore significant direct exposure of cornea to the compound through the tears was discounted. The presence of corneal muscarinic receptors was investigated to determine whether opacities could be related to direct, receptor-mediated events in the cornea; however, no specific binding of the muscarinic receptor radioligand [3H]quinuclidylbenzilate was detected. Because muscarinic agonist-induced opacities can be inhibited by scopolamine, the apparent lack of muscarinic receptors in the cornea indicates that the opacities are not a direct effect, but are instead secondary to muscarinic events at another site. To our knowledge, this is the first report of corneal opacities induced by a muscarinic agonist.

Body weight regulation in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Rats treated with a sublethal dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, 15 micrograms/kg) exhibited reduced feed intake and loss of body weight for the first 3 weeks after treatment. During the next 10 weeks, TCDD-treated rats maintained their body weight at a lower nearly constant percentage of that of control rats fed ad libitum. At no time did rats treated with TCDD exhibit hyperphagia which would have returned their weight to a normal level. Control rats pair-fed to TCDD-treated rats for more than 7 weeks displayed compensatory hyperphagia when permitted to feed ad libitum and their weight recovered to a near-normal level. The lower level of body weight in TCDD-treated animals was apparently due to a reduction in the regulation level or "set-point" for body weight. The following findings in TCDD-treated and control rats fed ad libitum supported this idea. First, when the reduced weight of the TCDD group was challenged by changes in the caloric density or palatability of the diet, TCDD-treated rats exhibited adjustments in feed intake and body weight that were essentially identical to those of control rats. Second, when body weight was manipulated by feeding a high-calorie diet or by restricting feed intake, both TCDD-treated and control rats quickly returned to weight levels from which they had been displaced. Third, carcass analyses conducted 7 weeks after treatment revealed that TCDD-treated rats had lower absolute amounts of body fat, protein, and water. However, when these constituents were expressed as percentages of total body weight no remarkable differences from the control were observed. Fourth, when TCDD-treated rats were induced to overeat and restore body weight to the same level as control rats fed ad libitum. TCDD-treated animals did not reassume a normal body composition but became obese. Obesity was also observed when control rats were induced to overeat. Thus, TCDD-treated rats regulate their body weight in the same fashion as control rats but at a weight regulation level or set-point that is markedly reduced.

Digestible energy and efficiency of feed utilization in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Treatment of male rats (300 to 325 g) with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, 15 or 50 micrograms/kg) caused dose-dependent reductions in body weight, feed and water intakes, and fecal output. Urine output, however, was not altered by TCDD. Fecal energy loss, as a percentage of daily feed energy intake (kcal/day), was similar in control and TCDD-treated rats as was the percentage of feed energy absorbed by the gastrointestinal tract, i.e., digestible energy. These findings dispel the long-standing proposal that a gross malabsorption syndrome is responsible for weight loss in TCDD-treated rats and place greater emphasis on hypophagia as the reason for weight loss. In support of a central role for hypophagia, it was found that control rats pair-fed to rats treated with a sublethal dose of TCDD (15 micrograms/kg) lost almost the same amount of weight. However, from 15 to 50 days post-treatment, the pair-fed animals consistently maintained their weight at a 10- to 15-g higher level than age-matched TCDD-treated rats. To determine why this weight difference occurs, the efficiency of feed utilization from Day 30 to 45 post-treatment in ad libitum fed control and TCDD-treated rats (15 micrograms/kg) that were maintaining different levels of body weight was compared. First, daily feed intakes of TCDD-treated and control rats were determined from Day 25 to 30 post-treatment. Second, weights of both groups were lowered by reducing feed intake in two successive 5-day periods to 50 and 10% of the respective ad libitum level. Third, on Days 40 to 45, both groups were refed their prereduction level of intake but reduced in proportion to the intervening loss in metabolic tissue mass. At each level of feed energy reduction, weight losses observed in the TCDD-treated and control rats were equivalent. Furthermore, although given only prerestriction amounts of feed that were indexed to their reduced metabolic body size (body wt kg 0.75), both TCDD-treated and control rats gained weight rapidly and at similar rates during the refeeding period. Thus, rats treated with a sublethal dose of TCDD displayed normal efficiency of feed utilization but did so at a subnormal level of weight. That is, just like control rats, TCDD-treated rats increased their efficiency of feed utilization (weight gain/feed intake) but only when their body weight was caused to fall below the lower weight maintenance level determined by the TCDD dose administered.(ABSTRACT TRUNCATED AT 400 WORDS)

Characterization of the wasting syndrome in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Treatment of male rats with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes a dose-dependent decrease in body weight, feed intake, resting and total oxygen consumption, and spontaneous motor activity. In animals treated with a nonlethal dose (5 or 15 micrograms/kg), feed intake and oxygen consumption recover within 3 weeks post-treatment to levels appropriate for the reduced weight of the animals. Rats treated with a lethal dose (50 micrograms/kg) lose weight continuously after treatment and typically die at a body weight approximately half that of age-matched, control rats. The similar dose and time dependencies for reduction of feed intake and weight suggest that hypophagia is the major factor responsible for weight loss in TCDD-treated rats. To determine if this hypophagia is a primary or secondary effect of TCDD treatment, rats whose body weights were reduced by food restriction prior to treatment (25 micrograms/kg) were studied. When allowed to feed ad libitum immediately after treatment, these animals exhibited relative hyperphagia and weight gain demonstrating that TCDD did not impair their capacity to feed. This finding suggests that the primary effect of TCDD is not on a system that controls feed intake, but rather on one that regulates body weight. It is proposed, as a heuristic model of the wasting syndrome, that TCDD treatment lowers a "set point" for regulated body weight in the rat in a dose-dependent fashion and that hypophagia serves, as a secondary response, to reduce the animal's weight to the lower regulation level determined by the dose administered.

Blood clearance tests for detecting 2,3,7,8-tetrachlorodibenzo-p-dioxin hepatotoxicity in rats and rabbits.

The objective was to determine if a blood clearance test would detect liver dysfunction in rats and rabbits treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Guinea pigs were included as a negative control, because TCDD does not produce detectable hepatotoxicity in this species. TCDD was given as a single dose to male rats (25 microgram/kg, po), rabbits (25 microgram/kg, ip) and guinea pigs (2 microgram/kg, ip) and liver function was assessed 10 days later by determining blood clearance of indocyanine green (ICG) and ouabain. Activity in serum of sorbitol dehydrogenase (SDH), glutamic pyruvic transaminase (SGPT) and gamma glutamyl transpeptidase (gamma GTP) were also measured and light microscopy performed on the liver. The results showed that hepatotoxicity in the rabbit could be detected by a reduction in ICG blood clearance and an elevation in SDH activity. In the rat, ouabain blood clearance was reduced and SDH activity elevated. None of the liver function tests were altered in the guinea pig. These results underline the usefulness of blood clearance tests using ICG and ouabain in detecting TCDD hepatotoxicity in animals.

Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on indocyanine green blood clearance in rhesus monkeys.

To assess effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on liver function adult male rhesus monkeys were treated with a single oral dose of acetone/corn oil (control) or 5, 25, or 75 micrograms/kg TCDD. Each monkey was used as its own control and indocyanine green (ICG) blood clearance and the following serum enzymes: glutamic pyruvate transaminase (SGPT), sorbitol dehydrogenase (SDH) and gamma glutamyl transpeptidase (gamma GTP), were measured at regular intervals for 4 weeks before and 17 weeks after treatment. In control monkeys ICG blood clearance and serum enzymes were similar before and after treatment. However, in the monkey that received 5 micrograms/kg TCDD there was a mild increase in ICG blood clearance followed by a slight decrease. The magnitude of this biphasic change was greater in monkeys that received 25 and 75 micrograms/kg TCDD and the decrease in clearance was invariably associated with a 1--2-week period before the monkeys died. SDH and SGPT activities were elevated at some time during the course of intoxication in all TCDD-treated monkeys but gamma GTP activity was not altered. The monkey treated with 5 micrograms/kg TCDD survived but monkeys treated with 25 and 75 micrograms/kg died 4--6 weeks after treatment. Light microscopy of the livers of TCDD-treated monkeys that died revealed fatty infiltration with minimal hepatocellular necrosis.